A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
A placebo-controlled pilot trial of 20 older adults with mild cognitive impairment titrated to 1 g/day of nicotinamide riboside for 10 weeks. NR significantly raised blood NAD+ but did not improve the primary cognitive outcome (MoCA) relative to placebo.
Evidence
6/10
Moderate Evidence
Sample
20
subjects
Duration
10 weeks
study period
Journal
GeroScience
Feb 2024
Key Findings
- 01
Blood NAD+ metabolome significantly increased with NR versus placebo
- 02
No significant improvement in MoCA (primary cognitive outcome)
- 03
NR was well tolerated at 1 g/day over 10 weeks
Structured Methods
- Study Design
- Clinical Trial
- Sample Size
- 20 subjects
- Study Duration
- 10 weeks
- Methodology
- Not reported
- Limitations
- Small sample size (n=20), short duration (10 weeks), single site — likely underpowered to detect a cognitive effect even if a modest one exists.
Citations & References
Orr ME, Kotkowski E, Ramirez P, Bair-Kelps D, Liu Q, Brenner C, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience.
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation